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Smaqy The product of the nm23 gene has been proposed as a candidate tumour metastasis suppressor
proten. A strong association has been observed between reduced expression of the n23 gene and acquisition
of metastatic behaviour in some tumour cells, ing breast cancer and mana, but not in others, such
as neuroblastoma and colon, crrvical and thyroid u. During the early gestation period both hun and
murine trophoblast cells exhibit in vitro invasive properties similar to those of neoplastic cells Such invasive
properties, however, disappear in the late stage of gestation. In the present study, we examined the abundance
of n23 mRNA from various fetal-mateal interface tissues (uterus, deadua, placenta and embryo) during
early (day 8), mid (day 14) and late (day 18) stages of gestation in CDI mice, in order to determine whether
nm23 plays any anti-invasive and/or biolgicl roles during gestation. nm23 was found to be expressed in all
the tissues during the early and mid stages of gestation. The expression levels were, however, variable among
different tisses and development stages. In the early stage, nn23 mRNA levels were the highest and similar
among tissues from the uterus, decidua, placenta and embryo. In the mid stage, the mRNA levels were
reduced signifiantly in the uterus, decidua and placenta, but not in the embryo. In the late stage, nm23
mRNA was fiuther reduced to the extent that it could not be seen in the decidua, was barely seen in the uterus
and was weakly present in the placenta. However, the mRNA level of the embryo in the late stage was still
high and similar to the early stage. We also eand vn23 expression in trophoblast ces from normal
human term placenta and a highly metastatic human choriocarcinoma cell line, JAR. nm23 expression was
signifntly higher in JAR than in normal placenta, indicating that nm23 does not appear to have an
anti-metastabc function in this cell lne. Sevral cytokines - interkin 2 (IL-2), tumour necrosis factor alpha
(TNF-a) and interferon gamma (IFN-y) - and prostaglaidin E2 (PGE2) known to modulate tumour growth
and metastasis were examined to determine whether they regulate nm23 exresson in JAR in vitro. The
B16FIO melanoma cell line was used as control. No effect was found in the JAR cell he, whereas TNF.41,
IFN-y and PGE2 down-regulated nm23 expression in the B16FIO cell line. We conclude that high nm23
expression may be assoated with cell proliferation and not correlate with its anti-invasive activity in the early
stage of gestation and in the JAR cell lne. The constant high n23 levl in the fetal tissue throughout the
gestation sugests that wn23 may play an important role in embryogeness. Given the exstence of a strong
association between reduced nm23 expsson and acquisition of metastatic behaviour in melanoma, the
observation of down-regulation of nm23 expression by cytokines in B16F1O melanoma cels but not in JAR
cells supports the notion that tissue-specific factors may be involved in the dissciation of nm23 expression
from its antimetastaic activity in JAR cells.
It has recently been suggested that the protein product of
nm23 gene plays an important role in tumour metastasis
suppresson (Rosengrd et al., 1989; Steeg et al., 1989). The
nm23 protein has substantial homology with the protein
encoded by a Drosophila abnormal wing discs (awd)
developmental gene and nucleoside diphosphate (NDP)
kinase, which catalyses the phosphorylation of nuleoside
diphosphate into nucleoside triphosphates (Biggs et al., 1990;
Kimura et al., 1990; Wallet et al., 1990). The abundance of
nm23 expression has been reported to be inversely correlated
with metastatic potential in several rodent metastasis model
systems: murine k-1735 melanomas (Steeg et al., 1988a-,
Leone et al., 1991), N-nitrosomethylurea-induced rat mam-
mary tumours (Steeg et al., 1988a), mouse mammary tumour
virus-induced tumours (Steeg et al., 1989) and ras ± adeno-
virus 2 Ela-co-transfected rat embryo fibroblasts (Steeg et al.,
1988b). The expression of human nm23 gene has also been
found to be lower in human breast cancer speimens with
high metastatic potential than in those with low metastatic
potential (Bevilacqua et al., 1989; Banmes et al., 1991; Hen-
nessy et al., 1991; Hirayama et al., 1991). Such a correlation,
however, has not been observed in some other human
tumours, such as colon cancer (Haut et al., 1991), neurobla-
toma (Hailat et al., 1991), some solid tumours including
breast carcinoma (Lacombe et al., 1991) and thyroid car-
cinomas (Zou et al., 1993). The expression of the gene is
increased equally in both high- and low-metastatic colon
cancers. In neuroblastoma and thyroid carcinoma nm23 exp-
ression is positively associated with advanced disease stage
(Hailat et al., 1991; Zou et al., 1993).
Trophoblast cells of the blastocyst and of the normal
first-trimester placenta share some phenotypic similarities
with malignant cells, e.g. rapid proliferation and ability to
invade neghbouring tissues, including basement membrane,
during the process of implantation and placental develop-
ment, but do not have the ability for unlimited growth or
metastasis, as few trophoblast cells can be identified in the
decidua, and trophoblasts rarely penetrate the maternal
blood vessels (Yagel et al., 1988). In the present study, we
examined the abundance of nm23 mRNA from various
fetal-maternal interface tissues (uterus, decidua, placenta
and embryo) during early (day 8), mid (day 14) and late (day
18) stages of gestation in CD1 mice, in order to determine
whether nm23 plays any anti-invasive and/or biological role
during gestation. We also examined the nm23 mRNA levels
in normal end-stage human placenta and in a highly meta-
static human JAR choriocarcinoma cell line. Several
cytokines and PGE2 known to modulate tumour growth and
metastasis were examined to determine whether they regulate
nm23 expression in JAR cells in vitro.
Material and nthods
Probes
A full-length human nm23-Hl cDNA probe was kindly
donated by P.S. Steeg of the National Cancer Institute,
Bethesda, MD, USA.
Tlhe oligonucleotide probe for 18S ribosomal RNA was
synthesised and the sequence is as follows: 5'-GGTCAGCG-
CTCGTCGGCATGTAATAG-3'.
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Mice
CD1 pregnant mice (Charles River, Margate, Kent, UK)
were used for the study of nn23 expression during gestation.
Six to eight mice were sacrificed on days 8, 14 and 18. The
uterus, decidua, placenta and embryo were removed from the
pregnant mice and immediately frozen in liquid nitrogen and
stored at -70°C until processed.
Tumour cell lines
The tumour cell lines used in this study were B16F10, a
highly metastatic murine melanoma cell line, kindly provided
by I.J. Fidler, Anderson Cancer Center, Houston, TX, USA,
and the human choriocarcinoma cell line JAR, obtained from
American Type Culture Collection, Rockville, MD, USA.
Both cell lines were maintained in RPMI-1640 medium sup-
plemented with 10% fetal calf serum (FCS), penicillin
(l00Um'l"), streptomycin (l00;Lg ml ') and fungizone
(25jtgml-1) at 37'C in a humidified atmosphere containing
5% carbon dioxide.
RNA extraction and Northern hybridisation
Total RNA was extracted by the guanidinium thiocyanate-
phenol-chloroform method (Chomczynski & Sacchi, 1987).
A 20ILg aliquot of total RNA was fractionated on 1%
agarose gel containing 2.2 M formaldehyde and blotted onto
nylon membranes (Hybond-N, Amersham) by capillary
transfer. The accuracy of RNA loading was monitored by
ethidium bromide staining and/or by hybridisation to an
oligoprobe for 18S ribosomal RNA as previously described
(Shi et al., 1991). The nm23-Hl cDNA probe was labelled
with [ax-3PJdCTP to a specific activity of 109 c.p.m.iLg'
using Pharmacia's random primer labelling kit. Hybridisation
was performed at 42°C for 18 h in 6 x SSPE, 10 mm EDTA,
5 x Denhardt's solution, 0.5% SDS, I00 Lg ml1' denatured
salmon testis DNA and 50% formamide. The membranes
were then washed twice in 2 x SSPE at 65'C and exposed to
Kodak XAR-5 film at - 70°C with intensifying screens.
Following autoradiography, band intensities were quanti-
tated by a Bio-Rad canning densitometry and normalised by
comparison with the 18S ribosomal band.
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RT-PCR and DNA sequencing analysis
A 5iLg aliquot of total RNA was reverse transcribed into
cDNA in a 15;LI volume, using Pharmacia's first-strand
cDNA synthesis kit. Two PCR primers were synthesised,
which flanked the coding region of nm23-H1 gene (5'-
CAGCCGGAGTTCAAACCTAA-3' and 5'-GGATGTG-
AAAAGCAATGTGG-3'). A 3 IlI volume of cDNA mix was
used for PCR in a 50 jIL volume. Samples were denatured at
94°C for 3 min and submitted to 30 cycles of amplification
under the following conditions: 40 s denaturation at 94'C,
40 s annealing at 56'C and 40 s extension at 720C.
DNA sequencing was performed by the dideoxy chain-
termination method after cloning the PCR products into TA
cloning vector (Invitrogen, CA, USA).
Regulation ofnm23 expression by cytokines and PGE2
B16F10 melanoma cells or JAR cells were cultured in 75 cm2
culture flasks (Costar, MA, USA) either alone or in the
presence of IL-2 (1,000 units ml-1, Sigma, MO, USA), TNF-
a (1,000 units ml-', Sigma), IFN-y (1,000 units ml-1, Sigma)
and PGE2 (250 ng ml-', Sigma) for 16 h at 37C in a
humidified incubator containing 5% carbon dioxide. Total
RNA was then prepared from 1 x 107 cells and probed for
nm23 expression.
Results
nm23 expression infetal-maternal interface tissues
nm23 mRNA level was examined in tissues from the uterus,
decidua, placenta and embryo on days 8, 14 and 18 (Figure
1). The expression level of nm23 gene was quantitated by
densitometry and compared with different stages of gestation
(Figure 2). As shown in Figures 1 and 2, nm23 was expressed
in all the tissues examined as early as day 8. The expression
levels were, however, variable among different tissues and
development stages. In the early stage (day 8), nm23 mRNA
levels were high and similar among tissues from the uterus,
decidua, placenta and embryo. In the mid stage (day 14), the
mRNA levels were reduced significantly in the uterus,
decidua and placenta, but not in the embryo. In the late
stage, nm23 mRNA levels were further reduced to the extent
that nm23 mRNA could not be seen in the decidua, was
barely seen in the uterus and was weakly present in the
placenta. The mRNA level in the embryo at this stage,
however, was still high and comparable to the early stage.
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Figue I Northern blot analysis of nm23 gene expression in
murine fetal-maternal interface tissues. Total RNA was electro-
phoresed on agarose/formaldehyde gel and blotted onto a nylon
membrane. Hybridisation was carried out with a full-length
nm23-HI cDNA probe (top) and an oligoprobe for 18S
ribosomal RNA to monitor RNA loading (bottom).
Figre 2 nm23 expression in murine fetal-maternal interface
tissues. The levels of nm23 mRNA were quantitated densitometri-
cally from Northern blots and compared in tissues from uterus,
decidua, placenta and embryo during different gestational stages.
The levels of 18S ribosomal RNA were used as an internal
standard to correct variations in the amount of RNA loaded.
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Therefore, nm23 expression was highest in the early stage as
compared to the mid (day 14) and late (day 18) stages of
gestation in tissues from the uterus, decidua, and placenta.
The mRNA level in the embryo was constantly high and not
reduced in the development of the embryo.
nm23 expression in hwnan choriocarcinoma cell line JAR
During the early stage of gestation, the high levels of nm23
expression in the placenta prompted us to ask whether this
was the result of its anti-metastatic protection against highly
invasive trophoblast cells or related to the rapid cell pro-
liferation. To this end, we compared nm23 expression in JAR
cells, highly invasive malignant cells, with those in normal
human placenta. As shown in Figure 3 the nm23 mRNA
level is, indeed, increased significantly in JAR cells.
To determine if point mutations, deletions or rear-
rangements of the nm23-HI gene caused the increased nm23
mRNA levels, we amplified the full-length nm23-Hl cDNA
from the JAR cell line by reverse transcription-polYmerase
chain reaction (RT-PCR). The resulting 540 bp PCR cDNA
product was cloned into TA vector and subsequently
sequenced. Two separate rounds of cDNA synthesis, PCR
amplification, cloning and complete cDNA sequencing were
Figwe 3 nm23 expression in normal human term placenta (lane
1) and the human choriocarcinoma cell line JAR (lane 2). Total
RNA was electrophoresed on agarose-formaldehyde gel and
blotted onto a nylon membrane. Hybridisation was carried out
with a full-ength nm23-H1 cDNA probe (top). Bottom: ethidium
bromide staining of the RNA loaded for Northern blot to
monitor the actual RNA loading. The positions of 18S and 28S
ribosomal RNA are indicated.
performed in order to rule out the possibility of enzymatic
errors in reverse transcription and, more commonly, in PCR
amplification with Taq polymerase. A total of five clones
(three from the first RT-PCR and two from the second
RT-PCR) were sequenced. The first RT-PCR examined
showed a change in codon 38 from CTG (leucine) to CIT
(leucine) in one of the three clones sequenced. The second
RT-PCR examined was completely identical with the pub-
lished cDNA sequences (Rosengard et al., 1989), indicating
that the change is an RT-PCR artifact (data not shown).
Thus, no mutation was found in the coding region of the
nm23-Hl gene.
Regulation ofnm23 expression by cytokines andprostaglandin
E2
It has been shown that several cytokines can modulate nm23
antimetastatic activity in melanoma cells in vivo (Leone et al.,
1991). It is not clear whether this is a direct or indirect effect
on nm23. It is also not clear whether this modulation can be
generalised to different types of tumours. In this regard, we
analysed nm23 mRNA levels in JAR choriocarcinoma cells,
which were cultured either alone or with IL-2, TNF-a, IFN-
-, IL-2 plus IFN-y or PGE2 for 16 h. PGE2 (not cytokine)
was included in the experiment because previous reports have
shown that PGE2 can promote tumour metastasis (Garaci et
al., 1987; Fulton et al., 1991; Young et al., 1991). B16FIO
melanoma cells were also included in the experiments as a
control. As shown in Figure 4a, IL-2 has no effect on nm23
expression in B16FIO melanoma cells. A 4-fold reduction of
nm23 transcripts was, however, observed when the cells were
cultured with TNF-4 or PGE2. A 2-fold reduction was noted
with either IFN-y alone or IFN-y plus IL-2 treatment. Sur-
prisingly, the cytokines and PGE2 have no effect on nm23
expression in JAR cells (Figure 4b).
The data presented herein demonstrate differential nm23 ex-
pression among fetal-maternal interface tissues during gesta-
tion, the highest level being found in early stage ofgestation.
The high level of nm23 expression in the fetal-matemal
interface tissues (uterus, decidua, placeta) may be involved
in the protection of maternal tissues from highly invasive
trophoblast cells during the early stage of gestation. The
progressive reduction in nm23 expression in uterus, decidua
and placenta coincides with the progression of gestation and
the reduction of invasiveness of trophoblast cells. This sug-
gests that the reduced nm23 mRNA may be associated with
ageing of these tissues and that the need for nm23 antimetas-
tatic activity is reduced in late stage of gestation. However,
as evidenced by the high level of nm23 mRNA in the human
choriocarcinoma cell line JAR, high nm23 expression appears
to be associated with rapid cell proliferation instead of its
antimetastatic activity, thus contradicting the above
hypothesis.
Tumours derived from JAR choriocarnoma cells are his-
topathologically similar to what has been described for spon-
taneous chonrocarcnomas of the uterus in women, in which
larg multinuceated cells (syncytiotrophoblasts) are common.
The invasiveness of JAR cells is similar to or even higher
than that of a highly metastatic mure melanoma line
B16FIO (Yagel et al., 1988), in which we have recently found
that increased nm23 expression in B16FIO cells is associated
with reduced pulmonary metastases (Parhar et al., submit-
ted). The mechaism rulting in the apparent dissociation of
high nm23 expression in JAR cells with its antmetastatic
function is not clear. Tissue-specific factors may be involved.
A recent study by MacDonald et al. (1993) has demonstrated
that autophosphorylation of nm23 protein at serine residues,
not its NDP kinase activity, correlates with suppression of
tumour metastatic potential. cAMP in vitro and forskolin in
vivo can inhibit the seine phosphorylation of nm23, suggest-
ing that this phosphorylation pathway is regulated in signalnm23 GENE EXPRESSION IN EMBRYOGENESIS 443
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Flgwe 4 Regulatio of nm23 expression by vanous cytokines and PGE2. Top: B16FlO cells (a) or JAR cells (b) were cultured
alone or with IL-2, TNF-a, IFN-7, IL-2 phls IFN-7, and PGE2 for 16 h. Total cellular RNA was earacted and probed with
fullength human n 13-H1 cDNA inset by Northern blot hybridization. Bottom: Ethidium bromide stainig of the RNA loaded
for Northern blot to monitor the atual RNA loadn The positions of 18S and 28S ribosomal RNA are indicated.
transduction. In JAR choriocarcinoma cells, a defect may be
present in this phosphorylation pathway which could prevent
nm23 expressg its antietastatic activity.
Association of high nm23 expression with rapid cell pro-
liferation has been inicated in certain tumours such as
neuroblastoma (Hailat et al., 1991), colon cancer (Haut et al.,
1991) and thyroid tumour (Zou et al., 1993), and supported
by a study showing that nm23-HI expression is related to cell
proliferation (Keim et al., 1992). It is known that the nm23
gene product has NDP kinase activity which provides intra-
cllular pools of nucleside triphosphates (excling ATP)
required for nucleic acid synthesis (Liotta & Steeg, 1990;
Gilles et al., 1991). In many systems, NDP kinases have been
found to be associated with GTP-binding proteins, incuding
elongation factor (Walton & Gill, 1975; Ohtsui &
Yokoyama, 1987), microtubules (Nickerson & Wells, 1984)
and p21 (Ohtsuki et al., 1986) or Gsm (Kimura & Shimada,
1988; Otero, 1990), s g that they are involved in
proceses such as protein synthesis, tubulin polymerisation in
the mitotc spindle and cytoskeleton and signal transduction
by supplying GTP to GTP-binding proteins. A recent study
has shown that the protein encoded by nm23-H2, one of two
cosely related human n23 genes, may be a trnciption
factor that turns on the cllular myc gene, which is known to
have ancer causg potential (Postel et al., 1993). Thus, a
higlevel of nm23 expresson could possibly induce pleot-
ropic effects on celular functions.
TIhe constant high klvel ofnm23 expression in the develop-
ing fetus during gestation is inteeti It suggets that nm23
may play an important role in embryogmesis. The study by
Lakso et al. (1992) has provided evidenc that nm23 protein
acaumulation is coincident with the functional differentiation
of multiple epithelal tissues in the developing mouse
fetus.
We have shown previously that TNF-a, IFN-y and PGE-2
can not only down-regulate n23 expression in B16F1O cell
line in vitro, but also modulate n23 antimetastatic activity
in vivo (Parhar et al., submitted). In vivo treatment with
TNF-4 or IFN-y or PGE2 in experimental mice injected with
B16F1O cells increased the pulmonary metastases and
reduced the overall survival period as compared with those
without any pretreatment (Parhar et al., submitted). The
effect of cytoknes on nm23 expression was, however, not
observed in JAR cells in this study. Given that a strong
association was found between reduced nm23 expression and
acquistion of metastatic behaviour in melanoma (Steeg et
al., 1988a; Leone et al., 1991) and that no such an associa-
tion exists in malignant trophoblast cells, the observation of
down-regulation of nm23 expression by some cytokines in
B16F1O cells but not in JAR cells supports the notion that
tissue-specific factors may be involved in the disociation of
nm23 expression from its antimetastatic activity in JAR cells.
It may also suggest that nm23 is not directly involved in the
tumour metastasis suppresson, but rather is an intermediate
product in the tumour meta suppression process, and its
expression and function could be modulated by tissue-specific
factors.
The human nm23-H2 gene has been discovered. It encodes
a protein with a predicted M, = 17,000 and is 88% identical
to the nm23-HI protein sequence (Stahl et al., 1991). The
nm23-HI probe we used does not efficiently distinguish
between the two nm23 mRNAs. Norhern blot hybridisation
of nm23-H2-specific probe to breast tumours and cell nes
shows that nm23-H2 expression was also reduced in high
metastatic potential tumour cells but to a lesser extent than
nm23-HI (Stahl et al., 1991), iting that the two genes
are rgulated independently. It is thus possible that the
observed nm23 expression in this gudy could be one of
several distin forms of nm23 that are variably expressed
and regulated in different cell types and thus play different
biological roles.
We wish to thank Dr Paticia S. Steeg for the generous gift of
nm23-Hl cDNA and Ms ColJeen Bilkey for editing the manu-
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